These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33498410)

  • 21. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
    Meex RCR; Watt MJ
    Nat Rev Endocrinol; 2017 Sep; 13(9):509-520. PubMed ID: 28621339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
    Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
    Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis.
    Zhang L; She ZG; Li H; Zhang XJ
    Clin Sci (Lond); 2020 Jul; 134(13):1775-1799. PubMed ID: 32677680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organokines in disease.
    Chung HS; Choi KM
    Adv Clin Chem; 2020; 94():261-321. PubMed ID: 31952573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Exercise Intervention on Mitochondrial Stress Biomarkers in Metabolic Syndrome Patients: A Randomized Controlled Trial.
    Chang JS; Namkung J
    Int J Environ Res Public Health; 2021 Feb; 18(5):. PubMed ID: 33668309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Various Exercise Regimens on Selected Exercise-Induced Cytokines in Healthy People.
    Domin R; Dadej D; Pytka M; Zybek-Kocik A; Ruchała M; Guzik P
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33572495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
    Su X; Kong Y; Peng D
    Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum hepatokines in dairy cows: periparturient variation and changes in energy-related metabolic disorders.
    Wang J; Zhu X; She G; Kong Y; Guo Y; Wang Z; Liu G; Zhao B
    BMC Vet Res; 2018 Aug; 14(1):236. PubMed ID: 30103741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms.
    Takahashi H; Kotani K; Tanaka K; Egucih Y; Anzai K
    Front Endocrinol (Lausanne); 2018; 9():588. PubMed ID: 30374329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines.
    Oh KJ; Lee DS; Kim WK; Han BS; Lee SC; Bae KH
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease.
    Musso G; Cassader M; Cohney S; Pinach S; Saba F; Gambino R
    Trends Mol Med; 2015 Oct; 21(10):645-662. PubMed ID: 26432021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective.
    Zhang Y; Wang Y; Liu J
    Genes Dis; 2023 May; 10(3):825-847. PubMed ID: 37396511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for Type 2 diabetes.
    Chen RB; Wang QY; Wang YY; Wang YD; Liu JH; Liao ZZ; Xiao XH
    Front Endocrinol (Lausanne); 2023; 14():1094458. PubMed ID: 36936164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD.
    Inagaki T
    Front Endocrinol (Lausanne); 2015; 6():147. PubMed ID: 26441837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in plasma concentrations and mRNA expression of hepatokines fetuin A, fetuin B and FGF21 in physiological pregnancy and gestational diabetes mellitus.
    Šimják P; Cinkajzlová A; Anderlová K; Kloučková J; Kratochvílová H; Lacinová Z; Kaválková P; Krejčí H; Mráz M; Pařízek A; Kršek M; Haluzík M
    Physiol Res; 2018 Nov; 67(Suppl 3):S531-S542. PubMed ID: 30484680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs.
    Kim KH; Lee MS
    J Endocrinol; 2015 Jul; 226(1):R1-16. PubMed ID: 26116622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
    Targher G; Marchesini G; Byrne CD
    Diabetes Metab; 2016 Jun; 42(3):142-56. PubMed ID: 27142870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice.
    Casteras S; Abdul-Wahed A; Soty M; Vulin F; Guillou H; Campana M; Le Stunff H; Pirola L; Rajas F; Mithieux G; Gautier-Stein A
    Diabetologia; 2016 Dec; 59(12):2645-2653. PubMed ID: 27631137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarcopenia and fatty liver disease.
    Kim JA; Choi KM
    Hepatol Int; 2019 Nov; 13(6):674-687. PubMed ID: 31705444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise.
    Lee S; Norheim F; Gulseth HL; Langleite TM; Kolnes KJ; Tangen DS; Stadheim HK; Gilfillan GD; Holen T; Birkeland KI; Jensen J; Drevon CA
    Physiol Rep; 2017 Mar; 5(5):. PubMed ID: 28270597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.